Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Darleukin + Fibromun in non-melanoma skin cancer with injectable lesions
2024-518530-92-00Phase 2Completed
- Sponsor
- Philogen
- Start
- Dec 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of darleukin and onfekafusp alfa in basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Philogen. Primary endpoint: Confirmed Best Overall Response Rate for basal cell carcinoma. Started Dec 2024; status: completed.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-518530-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518530-92-00.